PTHS
Pelthos Therapeutics Inc. AMEX Listed Jul 2, 2025$24.73
-1.08%
vs $25.00
Mkt Cap $86.0M
52w Low $18.19
33.9% of range
52w High $37.50
50d MA $27.28
200d MA $25.69
P/E (TTM)
—
EV/EBITDA
—
P/B
1.2x
Debt/Equity
0.9x
ROE
-111.4%
P/FCF
-2.0x
RSI (14)
29.50
ATR (14)
$2.08
Beta
3.99
50d MA
$27.28
200d MA
$25.69
Avg Volume
86.6K
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703 · Durham, NC 27703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | BMO | -2.82 | -6.62 | -134.8% | 28.91 | -3.8% | +0.1% | -5.0% | -5.8% | +0.8% | -1.1% | — |
| May 14, 2026 | BMO | -3.45 | -3.09 | +10.4% | 26.01 | +3.8% | +6.5% | -3.5% | -2.1% | +3.3% | +0.4% | — |
| Mar 19, 2026 | BMO | -3.95 | -6.87 | -73.9% | 22.97 | -1.9% | -9.7% | +6.1% | +0.0% | +0.4% | +2.9% | — |
| Nov 13, 2025 | BMO | -0.67 | -5.30 | -691.0% | 34.68 | -4.8% | -3.1% | -0.9% | -4.4% | -5.7% | -3.4% | — |
| Aug 13, 2025 | BMO | -5.82 | -5.38 | +7.6% | 18.18 | +2.3% | +4.3% | +10.5% | +1.4% | -3.5% | +4.4% | — |
| May 13, 2025 | BMO | -2.90 | -3.21 | -10.7% | — | — | — | — | — | — | — | — |
| Mar 27, 2025 | BMO | — | -3.23 | — | — | — | — | — | — | — | — | — |
| Nov 13, 2024 | BMO | -2.30 | -2.90 | -26.1% | — | — | — | — | — | — | — | — |
| Aug 13, 2024 | BMO | -3.10 | -3.07 | +1.0% | — | — | — | — | — | — | — | — |
| May 15, 2024 | BMO | — | -5.50 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $22.97 | $22.54 | -1.9% | -9.7% | +6.1% | +0.0% | +0.4% | +2.9% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.08 | $24.95 | +3.6% | -4.6% | -9.7% | +6.1% | +0.0% | +0.4% |
| Feb 26 | Roth Capital | Maintains | Buy → Buy | — | $23.00 | $23.00 | +0.0% | +0.0% | +14.6% | -8.3% | +0.1% | -4.9% |
| Jan 26 | Oppenheimer | Maintains | Outperform → Outperform | — | $24.75 | $24.52 | -0.9% | -0.9% | +5.6% | -4.6% | +4.4% | -6.8% |
| Nov 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $34.68 | $33.00 | -4.8% | -3.1% | -0.9% | -4.4% | -5.7% | -3.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Greenleaf PeterDir | — | Sell | 85 | $27.27 | $2K | 23,884 | +13.82% | -3.24% |
| Jul 2, 2026 | Greenleaf PeterDir | — | Sell | 712 | $26.00 | $19K | 23,969 | +13.82% | -3.24% |
| Jul 2, 2026 | Pauls MatthewDir | — | Sell | 94 | $27.36 | $3K | 14,364 | +13.82% | -3.24% |
| Jul 2, 2026 | Pauls MatthewDir | — | Sell | 692 | $26.00 | $18K | 14,458 | +13.82% | -3.24% |
| Jul 2, 2026 | Friedberg Ezra MDir | — | Sell | 24 | $27.33 | $656 | 81,042 | +13.82% | -3.24% |
| Jul 2, 2026 | Friedberg Ezra MDir | — | Sell | 534 | $26.03 | $14K | 81,066 | +13.82% | -3.24% |
| Jun 15, 2026 | Friedberg Ezra MDir | — | Sell | 59 | $27.94 | $2K | 81,600 | +7.37% | +1.74% |
| Jun 15, 2026 | Friedberg Ezra MDir | — | Sell | 224 | $27.12 | $6K | 81,659 | +7.37% | +1.74% |
| Jun 11, 2026 | Davis Todd CDir | — | Buy | 503 | $28.73 | $14K | 75,834 | +5.74% | +0.75% |
| Jun 11, 2026 | Davis Todd CDir | — | Buy | 35,445 | $27.80 | $986K | 75,331 | +5.74% | +0.75% |
| May 22, 2026 | Francis Knuettel IIOff | CFO, Treas & Secty | Sell | 1,500 | $26.84 | $40K | 11,316 | -0.77% | -0.76% |
8-K · 2.02
!! High
Pelthos Therapeutics Inc. -- 8-K 2.02: Earnings Results
Pelthos Therapeutics reported financial results via press release, with the detailed earnings information incorporated into the SEC filing for investor review.
Aug 13
8-K
Pelthos Therapeutics Inc. -- 8-K Filing
Pelthos Therapeutics must restate financial statements due to improper valuation of convertible debt provisions, including subordination terms and conversion rate reset features from its January 2026 issuance.
Aug 13
8-K · 7.01
! Medium
Pelthos Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Pelthos Therapeutics disclosed investor presentation materials via 8-K filing, signaling potential news regarding company developments, though the specific details require reviewing the attached exhibits.
May 28
8-K · 2.02
!! High
Pelthos Therapeutics Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 2.02
!! High
Ligand Pharmaceuticals Incorporated -- 8-K 2.02: Earnings Results
Ligand Pharmaceuticals reported Q1 2026 financial results, providing investors updated performance metrics and operational insights for assessing the company's financial health and strategic progress.
May 7
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Pathstone International disclosed material non-public information to certain parties, triggering Regulation FD requirements to simultaneously disclose publicly, suggesting the company made significant announcements that could impact stock valuation.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The CFO's departure effective April 10, 2026 signals potential financial uncertainty or strategic shifts at Ligand Pharmaceuticals and Path Therapeutics, requiring investors to monitor interim leadership decisions and financial guidance updates closely.
Apr 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate disclosure suggests PTHS disclosed material non-public information to select parties, requiring public dissemination to level the playing field for all investors.
Mar 19
Valuation
Market Cap
$86.0M
Enterprise Value
$59.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.02x
P/B
1.20x
P/S
1.98x
P/FCF
-2.05x
EV/EBITDA
—
Shares Out
1.9M
Financials (TTM)
Revenue
$43.3M
Net Income
-$71.6M
EBITDA
-$63.1M
Free Cash Flow
-$22.7M
Op Cash Flow
-$22.6M
EPS Basic
$-23.04
EPS Diluted
$-41.93
EPS Forward
$-9.77
Gross Margin
54.7%
Op Margin
-133.4%
Net Margin
-165.2%
Balance Sheet
Total Assets
$130.4M
Total Liab.
$91.5M
Total Equity
$38.9M
Cash
$18.0M
LT Debt
$31.4M
Book Value/Sh
$20.68
Debt/Equity
0.90x
Current Ratio
2.03
Quick Ratio
1.12
Returns & Growth
ROE
-111.4%
ROA
-33.2%
ROIC
-26.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-70.2%
Price Returns
2W
-10.1%
1M
-3.9%
3M
-6.6%
6M
-6.2%
12M
+4.6%
Technicals
52W High
$37.50
52W Low
$18.19
50d MA
$27.28
200d MA
$25.69
RSI (14)
29.50
ATR (14)
$2.08
Beta
3.99
Avg Volume
87K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$56.25
High
$60.00
Low
$50.00
Median
$57.50
Data updated apr 26, 2026 9:09pm
· Source: financialmodelingprep.com